🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Niharika B. Mettu

Duke University

ORCID: 0000-0002-7821-3298

Also affiliated with Duke Medical Center, Duke University Hospital, Duke Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer”.

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

JAMA Network Open(2022)10.1001/jamanetworkopen.2021.49040

N/A

3.5DataRank · unranked

127 citations

Fang‐Shu Ou, Tyler Zemla, Þorvarður R. Hálfdánarson, Heinz‐Josef Lenz, Rimini Breakstone +11 more

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

Investigational New Drugs(2021)10.1007/s10637-020-01044-8

N/A

1.6DataRank · unranked

46 citations

Tricia Kunst, Santhana Webb, Christina DeVisser, Christy Arrowood, Seth M. Steinberg +4 more

5MO Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase

Annals of Oncology(2022)10.1016/j.annonc.2022.01.068

N/A

0DataRank · unranked

3 citations

E. Lee, Ezra Y. Rosen, David R. Spigel, Martin Højgaard, S. Lheureux +15 more